NA
Lv2
110 积分
2021-09-06 加入
-
EP.12H.07 A Phase I Clinical Trial of Carfilzomib in Combination with Sotorasib in Patients with KRASG12C Mutated NSCLC
1小时前
求助中
-
Development of PI3Kα inhibitors for tumor therapy
6个月前
已完结
-
Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy
1年前
已完结
-
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1年前
已完结
-
Association of QTc Formula With the Clinical Management of Patients With Cancer
1年前
已完结
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
1年前
已完结
-
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
1年前
已完结
-
Emerging tyrosine kinase inhibitors for head and neck cancer
1年前
已完结
-
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial
1年前
已完结
-
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial
1年前
已完结